Tag Archives: Jim Greenwood

Jim Greenwood on the Road: Opening Bell at NASDAQ

Jim Ringing Nasdaq Bell

Jim Greenwood, BIO’s President and CEO, rang the opening bell this morning at the NASDAQ MarketSite in New York. Joining him on the stage were a number of BIO members and affiliates, including NewYorkBIO Executive Director Nathan Tinker, Pennsylvania Bio President Christopher Molineaux, DelawareBio Chairman Christopher Yochim, and BioNJ President Debbie Hart. Several BIO member companies were also represented, including Acorda Therapeutics President and CEO Ron Cohen, who also serves as Vice Chair of BIO’s Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Wall Street Journal Highlights Promising Gene Therapy Advances

Jim Greenwood

Yesterday, bluebird bio reported some very uplifting news at the annual meeting of the American Society of Hematology. Two patients with beta-thalassemia, a genetic disorder which normally requires regular blood transfusions, have been able to forgo transfusions for at least five months following a gene therapy treatment from bluebird. The Wall Street Journal’s Ron Winslow reports: Bluebird bio’s treatment involves extracting blood stem cells from a patient, treating them with a functioning version of the defective Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Jim Greenwood Op-Ed: Time to Fund Medical Countermeasures against Threats like Ebola

Jim Greenwood

On Friday, The Hill published an op-ed from BIO President and CEO Jim Greenwood calling on Congressional appropriators to fully fund federal biodefense programs, which partner with industry to develop medical countermeasures against Ebola as well as other threats like smallpox, anthrax, and botulism toxin. President Obama’s supplemental Ebola funding request last week asked Congress to appropriate $157 million in funding for BARDA and $238 million for the National Institutes of Health to support Ebola Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Member Company Achieves Significant Milestone in Advanced Biofuel Technology

abengoa-fermentation-tank-115x76

On Friday, October 17, 2014, Abengoa Bioenergy opened its 25-million gallon per year cellulosic ethanol biorefinery in Hugoton, Kansas.  Abengoa completed the construction of its facility in mid-August and began producing cellulosic ethanol at the end of September. The plant produces up to 25 million gallons a year using only raw biomass “second generation” for the production of ethanol, ie residues of agricultural crops and inedible stems and leaves that do not compete with grain for feed materials. Through Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Ebola Highlights Importance of Vaccine Development in Protecting Global Health

21st-Century-Cures--Free

The current Ebola crisis shows how government regulators and research institutions, global health organizations, and biopharmaceutical research companies can work collaboratively and efficiently to speed the development of novel vaccines and therapeutics in response to an urgent global health problem. Yet just as importantly, it underscores the need to move innovation forward before a crisis breaks out in order to prevent illness and suffering, and save the lives of countless people around the world. Vaccines Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,